Avanos Medical
Market Cap
US$1.3b
Last Updated
2020/04/09 04:12 UTC
Data Sources
Company Financials +
Executive Summary
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients’ quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet and fair value.
Similar Companies
Share Price & News
How has Avanos Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AVNS's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
7.2%
AVNS
10.2%
US Medical Equipment
9.4%
US Market
1 Year Return
-40.2%
AVNS
2.1%
US Medical Equipment
-6.8%
US Market
Return vs Industry: AVNS underperformed the US Medical Equipment industry which returned 0.2% over the past year.
Return vs Market: AVNS underperformed the US Market which returned -8.1% over the past year.
Shareholder returns
| AVNS | Industry | Market | |
|---|---|---|---|
| 7 Day | 7.2% | 10.2% | 9.4% |
| 30 Day | -17.9% | 0.9% | -3.9% |
| 90 Day | -19.3% | -12.1% | -16.5% |
| 1 Year | -40.2%-40.2% | 2.9%2.1% | -4.8%-6.8% |
| 3 Year | -28.8%-28.8% | 57.1%52.9% | 23.4%15.2% |
| 5 Year | -46.5%-46.5% | 89.2%69.8% | 41.3%25.7% |
Price Volatility Vs. Market
How volatile is Avanos Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Read This Before Selling Avanos Medical, Inc. (NYSE:AVNS) Shares3 weeks ago | Simply Wall St
Does Avanos Medical, Inc.'s (NYSE:AVNS) CEO Salary Reflect Performance?1 month ago | Simply Wall St
Avanos Medical, Inc. Just Released Its Full-Year Results And Analysts Are Updating Their EstimatesValuation
Is Avanos Medical undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AVNS ($26.4) is trading below our estimate of fair value ($74.78)
Significantly Below Fair Value: AVNS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AVNS is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: AVNS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AVNS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AVNS is good value based on its PB Ratio (1x) compared to the US Medical Equipment industry average (3.1x).
Next Steps
Future Growth
How is Avanos Medical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
115.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVNS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: AVNS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AVNS's is expected to become profitable in the next 3 years.
Revenue vs Market: AVNS's revenue (4.2% per year) is forecast to grow slower than the US market (6.9% per year).
High Growth Revenue: AVNS's revenue (4.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AVNS's Return on Equity is forecast to be low in 3 years time (5%).
Next Steps
Past Performance
How has Avanos Medical performed over the past 5 years?
28.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVNS is currently unprofitable.
Growing Profit Margin: AVNS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVNS is unprofitable, but has reduced losses over the past 5 years at a rate of 28% per year.
Accelerating Growth: Unable to compare AVNS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVNS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.4%).
Return on Equity
High ROE: AVNS has a negative Return on Equity (-3.63%), as it is currently unprofitable.
Next Steps
Financial Health
How is Avanos Medical's financial position?
Financial Position Analysis
Short Term Liabilities: AVNS's short term assets ($538.5M) exceed its short term liabilities ($212.5M).
Long Term Liabilities: AVNS's short term assets ($538.5M) exceed its long term liabilities ($321.9M).
Debt to Equity History and Analysis
Debt Level: AVNS's debt to equity ratio (19.6%) is considered satisfactory.
Reducing Debt: AVNS's debt to equity ratio has reduced from 42% to 19.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVNS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AVNS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Avanos Medical's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVNS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AVNS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVNS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVNS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVNS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.7yrs
Average management tenure
CEO
Joe Woody (53yo)
2.83s
Tenure
US$5,023,674
Compensation
Mr. Joseph F. Woody, also known as Joe, has been Chief Executive Officer and Director of Halyard Health, Inc. since June 26, 2017. Mr. Woody served as the Chief Executive Officer and President of Acelity H ...
CEO Compensation Analysis
Compensation vs Market: Joe's total compensation ($USD5.02M) is about average for companies of similar size in the US market ($USD4.69M).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.83yrs | US$5.02m | 0.30% $3.8m | |
| Senior Vice President of Legal & Government Relations | no data | US$940.93k | 0.17% $2.1m | |
| Senior Vice President of Business Strategy | 0.25yr | US$911.19k | 0.081% $1.0m | |
| Senior Vice President of International | 2yrs | US$836.80k | 0.0050% $63.2k | |
| Senior Vice President of Global Supply Chain & Procurement | 1.33yrs | US$1.04m | no data | |
| Senior VP & CFO | 0.25yr | no data | no data | |
| VP, Controller & Chief Accounting Officer | no data | no data | 0.040% $510.1k | |
| VP of FP&A and Investor Relations and Treasurer | no data | no data | no data | |
| Senior VP & Chief Human Resources Officer | 5.5yrs | US$1.03m | no data | |
| Senior Vice President of Global R&D | no data | no data | no data |
1.7yrs
Average Tenure
53yo
Average Age
Experienced Management: AVNS's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.83yrs | US$5.02m | 0.30% $3.8m | |
| Independent Director | 5.5yrs | US$250.00k | 0.052% $656.6k | |
| Independent Director | 4.33yrs | US$265.00k | 0.051% $639.5k | |
| Independent Chairman of the Board | 2.58yrs | US$365.00k | 0.045% $562.8k | |
| Independent Director | 5.5yrs | US$270.00k | 0.052% $656.1k | |
| Independent Director | 5.5yrs | US$250.00k | 0.052% $657.2k | |
| Independent Director | 5.5yrs | US$265.00k | 0.052% $655.8k | |
| Independent Director | 5.5yrs | US$265.00k | 0.052% $655.8k | |
| Independent Director | 5.17yrs | US$250.00k | 0.050% $634.5k |
5.5yrs
Average Tenure
62yo
Average Age
Experienced Board: AVNS's board of directors are considered experienced (5.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Avanos Medical, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Avanos Medical, Inc.
- Ticker: AVNS
- Exchange: NYSE
- Founded: 2014
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$1.261b
- Shares outstanding: 47.76m
- Website: https://avanos.com
Number of Employees
Location
- Avanos Medical, Inc.
- 5405 Windward Parkway
- Suite 100 South
- Alpharetta
- Georgia
- 30004
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AVNS | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Oct 2014 |
| 8HH | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Oct 2014 |
Biography
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients’ quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. Its product portfolio includes digestive health products, including enteral feeding tubes and solutions; respiratory health products, such as closed airway suction systems and oral care kits; and acute pain products comprising surgical pain pumps, and cold and compression therapy systems, as well as interventional pain management solutions that include minimally invasive interventional pain therapies. The company sells its products under the MIC-KEY, CORPAK, NEOMED, BALLARD, MICROCUFF, ENDOCLEAR, ON-Q, AMBIT, GAME READY, and COOLIEF brand names. It markets its products directly to hospitals and other healthcare providers, and through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/04/09 04:12 |
| End of Day Share Price | 2020/04/08 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.